Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-09-06
2005-09-06
Henley, III, Raymond J. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
06939873
ABSTRACT:
The present invention relates to novel non-sedating barbituric acid derivatives, pharmaceutical compositions containing them and methods of neuroprotection in cases of cerebral ischemia, head trauma and other acute neurologic injuries, and prevention of resulting neuronal damage. The invention also relates to the use of non-sedating barbituric acid derivatives given in a manner and dosage effective to produce blood levels and brain levels of these drugs and/or their active metabolites sufficient to provide a therapeutic effect.
REFERENCES:
patent: 2673205 (1954-03-01), Hoffmann et al.
patent: 4060528 (1977-11-01), Janssen et al.
patent: 4578503 (1986-03-01), Ishikawa et al.
patent: 4628056 (1986-12-01), Levitt et al.
patent: 4894459 (1990-01-01), Bod et al.
patent: 4914226 (1990-04-01), Di Trapani et al.
patent: 5120850 (1992-06-01), Bod et al.
patent: 5128477 (1992-07-01), Bod et al.
patent: 5750766 (1998-05-01), Krummel et al.
patent: 5756815 (1998-05-01), Knell
patent: 5808066 (1998-09-01), Krummel et al.
patent: 6051737 (2000-04-01), Kim et al.
patent: 6093820 (2000-07-01), Gutman et al.
patent: 6156925 (2000-12-01), Meyer et al.
patent: 6184238 (2001-02-01), Takano et al.
patent: 6262067 (2001-07-01), Allen et al.
patent: 6372757 (2002-04-01), Johns et al.
patent: 6756379 (2004-06-01), Moros et al.
patent: 1939787 (1970-02-01), None
patent: 2622981 (1977-12-01), None
patent: 4028040 (1992-03-01), None
patent: 726252 (1996-08-01), None
patent: 726252 (1996-08-01), None
patent: 1 083 172 (2001-03-01), None
patent: WO 99/18084 (1999-04-01), None
patent: WO 01/79185 (2001-10-01), None
patent: WO 02/007729 (2002-01-01), None
Thacker et al., “Method for the Determination of 5,5-Diphenylbarbituric Acid and Separation from 1,3-Dimethoxymethyl-5,5-Diphenylbarbituric Acid in Plasma by High Performance Liquid Chromatography,” J. Chromatography B, 710:149-155 (1998).
Raines et al., “Conversion of Dimethoxymethyl-Diphenylbarbituric Acid (DMMDPB) to Diphenylbarbituric Acid (DPB) in the Dog,” The FASEB J., 13(4):A475, Abstract 394.2 (1999).
Raines et al., “The Effects of 5,5-Diphenylbarbituric Acid on Experimental Seizures in Rats: Correlation between Plasma and Brain Concentrations and Anticonvulsant Activity,” Epilepsia, 16:575-581 (1975).
Raines et al., “A Comparison of the Anticonvulsant, Neurotoxic and Lethal Effects of Diphenylbarbituric Acid Phenobarbital and Diphenylhydantoin in the Mouse,” J. Pharmacology and Experimental Therapeutics, 186(2):315-322 (1973).
Tagmana et al., Helv. Chim. Acta 35, 1541-1549 (1952).
Salmon-Legagneur et al., “Sur les acides α-phényl α-alcoyl (ou phénoalcoyl) glutariques”, Comptes Rendus de l'Académie des Sciences, (Mar. 3, 1952) p. 1060.
Salmon-Legagneur et al., “Recherches dans la série des diacides αα-disubstitués et de leurs dérivés. III. Les acides α-phénol α-alcoyl (ou phénoalcoyl) glutariques et leurs principaux dérivés”, Bull. Soc. Chim. France (1953) p. 70.
The Merck Index, 10th Ed., (Merck & Co., Inc., Rahway, NJ) (1983) p. 544 (entry 3697).
Casara et al., “Synthesis of acid stable fluorinated acyclonucleosides as potential antiviral agents,” Tetrahedron Letters, 32(31) (1991), pp. 3823-3826.
Foye, “Principles of Medicinal Chemistry,” 3rd. ed. (1990) pp 164, 179.
Karger et al., “Methoxymethyl Methanesulfonate, A Novel Active Oxyalkylating Agent, ” J. Am. Chem. Soc., 91:5663 (1969).
Sircar, J. Chem. Soc. (1927) 1252-1256.
Gao et al., “Physical Chemical Stability of Warfarin Sodium,” AAPS Pharmasci (2001) 3(1) Article 3.
Appendix 1 of U.S.S.N. 60/352,273, filed Jan. 30, 2002: Chemical Derivative Chart (total of 8 pages).
Appendix 2 of U.S.S.N. 60/352,273, filed Jan. 30, 2002: Reference to Chemical Derivatives (total of 3 pages).
Appendix 3 of U.S.S.N. 60/352,273, filed Jan. 30, 2002: CANCERLIT . . . (total of 9 pages).
Appendix 3 of U.S.S.N. 60/352,273, filed Jan. 30, 2002: PubMed search results printout of Jan. 15, 2002 (total of 7 pages).
Appendix 3 of U.S.S.N. 60/352,273, filed Jan. 30, 2002: MEDLINEplus printout of Jan. 15, 2002: Barbiturates (Systemic) (total of 14 pages).
PubMed search results printout of Dec. 27, 2002 (total of 3 pages).
Masuda et al., “Relationships Between Plasma Concentrations of Diphenylthydantoin, Phenobarbital, Carbamazepine, and 3-Sulfanoylmethyl- 1, 2-Benzisoxazole (AD-810), a New Anticonvulsant Agent, and Their Anticonvulsant or Neurotoxic Effects in Experimental Animals”, Epilepsia, 20, pp. 623-633, (1979).
Bhardwaj et al., “Pentobarbital inhibits extracellular release of dopamine in the ischemic striatum”, Journal of Neural Transmission [Gen Sect], 82, pp. 111-117, (1990).
McElvain, “5,5-Diphenylbartintric Acid”, 57, pp. 1303-1304, (1935).
Gesson et al., “A practical method for N-alkylation of succinimide and glutarimide”, Bull Soc. Chim. Fr. 129, pp. 227-231, (1992).
Kamata et al., “Studies of Antitumor-Active 5-Fluorouracil Derivatives I Synthesis of N-Phtlalidyl 5-Flourouracil Derivatives”, Chem. Pharm. Bull, 33 (8), pp. 3160-3175, (1985).
Samour et al., “Anticonvulsants, I. Alkoxymethyl Derivatives of Barbituates and Diphenylhydantoin”, Journal of Medicinal Chemistry, 14 (3), pp. 187-189, (1971).
Raines et al., “Differential Selectivity of Several Barbiturates on Experimental Seizures and Neurotoxicity in the Mouse”, Epilepsia, 20, pp. 105-113, (1979).
Loudon, “Organic Chemistry”, Addison-Wesley (1984), pp. 617, 721-722, 1061-1064, 1086-1088, 1194.
Corkill et al., Surg. Neurol., pp. 147-149 (1976).
Hoff et al., Stroke, 6, pp. 28-33, (1975).
Levy and Brierley, “Delayed pentobarbital administration limits ischemia brain damage in gerbils”, Annals of Neurology, 5(1), pp. 59-64, (1979).
Lightfoote et al., Stroke, 8, pp. 627-628, (1977).
Pulsinelli and Brierley, “A new model of bilateral hemospheric ischemia in the unanesthetized rat”, Stroke, May—Jun. 10(3), pp. 267-272, (1979).
Raines et al., Epilepsia 1996, 37:Suppl. 5.
Ginsberg, “Animal Models of Global and Focal Cerebral Ischemia,” Chapter 34 in Welsh KMA et al.,Primer on Cerebrovascular Diseases, Academic Press, New York (1997).
Miller, ed., “Stroke Therapy: Basic, preclinical, and clinical directions”, Wiley (1999).
Brint et al., “Focal brain ischemia in the rat: Methods for reproducible neocortical infarction using tandem occlusion of the distal middle cerebral and ipsilateral commoa carotid arteries”, J. Cerebral Blood Flow Metab., 8, pp. 474-485, (1988).
Garcia et al., “Neurological deficit and extent of neuronal necrosis attributable to middle cerebral artery occlusion in rats, Statistical validation”, Stroke, 26(4), pp. 627-634, (1995).
Garcia et al., “Neuronal necrosis after middle cerebral artery occlusion in Wistar rats progresses at different time intervals in the caudoputamen and the cortex”, Stroke, 26(4), 636-643 (1995).
Pulsinelli et al., “Temporal profile of neuronal damage in a model of transient forebrain ischemia”, Annals of Neurology, May 11(5), 491-498, (1982).
Raines et al., J. Exp. Biol. (Abstracts) Abstract No. 895 (Apr. 14-17, 1996).
Gutman Daniella
Moros Daniel A.
Henley III Raymond J.
Taro Pharmaceuticals Industries Limited
LandOfFree
Non-sedating barbituric acid derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Non-sedating barbituric acid derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Non-sedating barbituric acid derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3430624